References
- Ehringer H, Hornykievicz O. [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system.]. Klin Wochenschr 1960;38:1236-9
- Ahlskog JE. Beating a dead horse: dopamine and Parkinson disease. Neurology 2007;69(17):1701-11
- Liu Y, Edwards RH. The role of vesicular transport proteins in synaptic transmission and neural degeneration. Annu Rev Neurosci 1997;20:125-56
- Sulzer D, Zecca L. Intraneuronal dopamine-quinone synthesis: a review. Neurotox Res 1999;1(3):181-95
- Schuldiner S, Shirvan A, Linial M. Vesicular neurotransmitter transporters: from bacteria to humans. Physiol Rev 1995;75(2):369-92
- Guillot TS, Miller GW. Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons. Mol Neurobiol 2009;2:149-70
- Liu Y, Peter D, Roghani A, et al. A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter. Cell 1992;70(4):539-51
- Wang YM, Gainetdinov RR, Fumagalli F, et al. Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine. Neuron 1997;19(6):1285-96
- Takahashi N, Miner LL, Sora I, et al. VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc Natl Acad Sci USA 1997;94(18):9938-43
- Fon EA, Pothos EN, Sun BC, et al. Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action. Neuron 1997;19(6):1271-83
- Caudle WM, Richardson JR, Wang MZ, et al. Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J Neurosci 2007;27(30):8138-48
- Lohr KM, Bernstein AI, Stout KA, et al. Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo. Proc Natl Acad Sci USA 2014;111(27):9977-82
- Pifl C, Rajput A, Reither H, et al. Is Parkinson’s disease a vesicular dopamine storage disorder? Evidence from a study in isolated synaptic vesicles of human and nonhuman primate striatum. J Neurosci 2014;34(24):8210-18
- Goldstein DS, Sullivan P, Holmes C, et al. Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson’s disease. J Neurochem 2013;126(5):591-603
- Rilstone JJ, Alkhater RA, Minassian BA. Brain dopamine-serotonin vesicular transport disease and its treatment. New Engl J Med 2013;368:543-50
- Glatt CE, Wahner AD, White DJ, Ruiz-linares A. Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women. Hum Mol Gen 2006;15(2):299-305
- Brighina L, Riva C, Bertola F, et al. Analysis of vesicular monoamine transporter 2 polymorphisms in Parkinson’s disease. Neurobiol Aging 2013;34(6):1712.e9-13
- Osherovich L. Priming the PD pump. Sci Exch 2014;7:26- doi:10.1073/pnas.1402134111